Well-Life COVID-19 / Influenza A&B Rapid Test (25/bx)

• Detects SARS-CoV-2, Influenza A/B Antigens in a Single Test
• Provides Qualitative Results in Approximately 10 Minutes
• Includes 25 Complete Tests per Box
• Designed for Professional Point-of-Care Testing
• Features Instrument-Free Visual Interpretation
• Stores at 2°C–30°C (36°F–86°F) .

The Clarity Diagnostics WELLlife COVID-19 / Influenza A&B Rapid Test is a rapid lateral flow immunochromatographic assay intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B antigens from anterior nasal swab specimens. Intended for professional in vitro diagnostic use, the assay delivers results in approximately 10 minutes and enables three respiratory pathogens to be evaluated using a single test cassette.

✔ COVID-19 & FLU A/B DETECTION | ✔ RESULTS IN 10 MINUTES | ✔ 25 TESTS PER BOX

MULTIPLEX RESPIRATORY TESTING

THREE-IN-ONE DETECTION: Simultaneously detects and differentiates SARS-CoV-2, Influenza A, and Influenza B antigens from a single anterior nasal swab specimen collected from individuals with signs and symptoms of respiratory infection, helping distinguish common viral respiratory infections with one assay.

RAPID QUALITATIVE RESULTS: Visual test and control lines provide results in approximately 10 minutes without requiring an analyzer or other laboratory instrumentation.

INTENDED USE: The assay is intended for testing symptomatic individuals within the timeframe, and results should always be interpreted together with patient history, clinical presentation, and other laboratory findings.

COMPLETE TESTING SOLUTION

25-TEST KIT: Each package contains 25 test cassettes, prefilled extraction tubes, sterile swabs, a workstation, and the manufacturer's Instructions for Use for routine professional testing.

INTERNAL PROCEDURAL CONTROL: Each test incorporates an internal procedural control that verifies proper specimen migration and reagent performance according to the manufacturer's Instructions for Use.

STORAGE CONDITIONS: Store the kit at 2°C–30°C (36°F–86°F) until the expiration date indicated on the product labeling.

The Clarity Diagnostics WELLlife COVID-19 / Influenza A&B Rapid Test offers an efficient approach to respiratory screening by combining SARS-CoV-2, Influenza A, and Influenza B antigen detection into a single rapid assay, helping healthcare professionals evaluate symptomatic patients while simplifying diagnostic workflows.

**FDA Disclaimer: This combination test is not FDA cleared or approved, but only authorized under an Emergency Use Authorization for use by authorized laboratories. It is authorized for the rapid detection of proteins from SARS-CoV-2, Influenza A and B, and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

WARNING: This product can expose you to chemicals known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.